Table 1.
mAbs under investigation for prophylaxis or therapy of SARS-CoV-2/COVID-19
| Name | Alternate name(s) | Company | Phase | Clinical trial identifier (disease indication) | Target population | Route | Dose (g) | Study name | Fc | PDB ID | Source and VH germline (% identity) | RBD site | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIR-7831 VIR-7832 | S309 GSK4182136 sotrovimab | Vir Biotechnology GSK | 2/3 EUA | NCT04545060 (early treatment) | at-risk adults | IV | 0.5 | COMET-ICE | LS | 7JX3 | SARS-CoV-immune donor VH3–23 (96.5%) | IV/class 3 | Cathcart et al., 2021; Gupta et al., 2021; Lempp et al., 2021; Pinto et al., 2020; Tortorici et al., 2021 |
| 2 | NCT04634409, VIR-7831+ bamlanivimab (early treatment) | adults | IV | 0.5 + 0.7 | BLAZE-4 | LS | |||||||
| 3 | NCT04501978 (late treatment) | hospitalized | IV | 0.5 | ACTIV-3 | LS | |||||||
| 1b/2a | (UK) (1b–2a) (early treatment) (VIR-7831 versus VIR-7832) | at-risk adults | IV | 0.5 | AGILE | LS-GAALIE versus LS | |||||||
| 2 | NCT04779879 (safety and pharmacokinetics) | adults | IV/IM | 0.5 | COMET-PEAK | LS | |||||||
| REGN-COV2 (REGN10933, REGN10987 not co-formulated) | casirivimab imdevimab | Regeneron | 1/2/3 | NCT04426695 (late treatment) | hospitalized | IV | 2.4 | Study 2066 | WT | 6XDG | SARS-CoV-2-immunized huIg mice (REGN10987) and SARS-CoV-2 donor (REGN10987) VH3–11 (98.6%) VH3–30 (98.6%) | Ia/class 1 | Baum et al., 2020a, 2020b; Copin et al., 2021; Hansen et al., 2020; Weinreich et al., 2021 |
| 8 | |||||||||||||
| 3 | NCT04452318 (household contact prevention) | adults/pediatrics | SC/IM | 1.2 | Study 2069 | ||||||||
| 3 | NCT04381936 (late treatment) | 12 years and older (hospitalized) | IV | 8 | RECOVERY | ||||||||
| 1/2/3 EUA | NCT04425629 (early treatment) | adult/pediatrics and pregnant | IV | 2.4 | Study 2067 | ||||||||
| 8 | |||||||||||||
| 2 | NCT04666441 (early treatment dose ranging study) | adults | IV/SC | ||||||||||
| 1 | NCT04519437 (safety repeat dosing) | adults | SC | Study 2093 | |||||||||
| LY-CoV016 | CB6, JS016, LY3832479, etesevimab | AbCellera Eli Lilly | N/A | N/A | N/A | N/A | N/A | N/A | LALA | 7C01 | SARS-CoV-2-immune donor VH3–66 (99.7%) | Ia/class 1 | Shi et al., 2020 |
| LY-CoV555 | Ab169 LY3819253 bamlanivimab | 1 | NCT04411628 (healthy volunteer) | adults | IV | BLAZE-5 | WT | 7KMG | SARS-CoV-2-immune donor VH1–69 (99.7%) | Ib/class 2 | Chen et al., 2021a; Gottlieb et al., 2021; ACTIV-3/TICO LY-CoV555 Study Group et al., 2021; Jones et al., 2021 | ||
| 2 | NCT04701658 (early treatment) | 12 years and older | IV | BLAZE-5 | |||||||||
| 2/3 | NCT04518410 (early treatment) | adults | IV | ACTIV-2 | |||||||||
| 4 | NCT04656691 (early treatment, at-home infusion) | older adults | IV | UNITED | |||||||||
| NCT04603651 (expanded access) | 12 years and older | IV | ACTIV-2 | ||||||||||
| LY-CoV555 and LY-CoV016 | CB6, JS016, LY3832479, etesevimab and Ab169 LY3819253 bamlanivimab | 3 | NCT04497987 prevention in nursing home residents and staff (post-exposure prophylaxis?) | adults | IV | BLAZE-2 | |||||||
| EUA | NCT04427501 (early treatment) | 12 years and older | IV | BLAZE-1 | |||||||||
| AZD7442 (cocktail of AZD8895 and AZD1061) | COV2-2196 | AstraZeneca | 3 | NCT04625725 (pre-exposure prophylaxis) | adults | IM | 0.15+0.15 | PROVENT | TM/YTE | N/A | SARS-CoV-2-immune donor VH1–58, VH3–15 | Ia/class 1 Ib/class 2 | Dong et al., 2021; Suryadevara et al., 2021; Zost et al., 2020 |
| COV2-2130 | 3 | NCT04625972 (post-exposure prophylaxis) | adults | IM | 0.15+0.15 | STORM CHASER | |||||||
| 3 | NCT04723394 (early treatment) | adults | IM | 0.6 | TACKLE | ||||||||
| 3 | NCT04501978 (late treatment) | hospitalized | IM | ACTIV-3 | |||||||||
| BRII-196 | 1F11 | Brii Biosciences | 1 | NCT04479631 (safety) | healthy volunteers | IV | 1 | ? | 7CDI | SARS-CoV-2-immune donor VH3–53 (?) | Ia/class 1 | Ju et al., 2020 | |
| BRII-198 | 1 | NCT04479644 (safety) | healthy volunteers | IV | 1 | ? | N/A | ? | |||||
| BRII-196 and BRII-198 combination | 2 | NCT04770467 (early treatment) | adults | IV | |||||||||
| 3 | NCT04501978 (late treatment) | hospitalized | IV | 1+1 | ACTIV-3 | ||||||||
| CT-P59 | regdanvimab | Celltrion | 2/3 EUA in South Korea | NCT04602000 (early treatment) | at-risk adults | IV | 40 mg/kg | ? | 7CM4 | SARS-CoV-2-immune donor VH-70 (?) | Ia/class 1 | Du et al., 2020; Kim et al., 2021; Ryu et al., 2021 | |
| ADG20 | ADG-2 parent ADI-55688 | Adagio | 1/2/3 | NCT04805671 (early treatment) | adults | IM/IV | 1 dose | WT/half-life ext. (?) | N/A | SARS-CoV-immune donor VH1–69? | Ia/class 1 | Dejnirattisai et al., 2021; Rappazzo et al., 2021; Wec et al., 2020 | |
| IIa/class 4 | |||||||||||||
| BGB-DXP593 | BD-368-2 | BeiGene Singlomics | 2 | NCT04551898 (early treatment) | adults | IV | 3 doses | ? | 7CHH | SARS-CoV-2-immune donor VH3–23 (?) | Ib/class 2 | Cao et al., 2020 | |
| ABBV-47D11 | 47D11 | AbbVie | 1 | NCT04644120 (safety and late treatment) | hospitalized | IV | 3 doses | ? | N/A | SARS-CoV-immunized huIg mice, N/A | ? | Wang et al., 2020 | |
| ABBV-2B04 | 2B04 | ? | N/A | RBD-immunized mice (B6), humanized? | Ia/class 1 | Alsoussi et al., 2020; Chen et al., 2021b; Liu et al., 2021b |
huIg, humanized immunoglobulin; IV, intravenous; IM, intramuscular; N/A, not available; SC, subcutaneous; WT, wild type.